Recruiting

Long-term Iron Absorption and Loss in Overweight/Obese Middle-aged Women

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This observational study aims to calculate the long-term iron absorption and loss in overweight or obese middle-aged women, determining the net iron gain by subtracting iron loss from iron absorption.

What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Body Weight+5

+ Nutrition Disorders

+ Nutritional and Metabolic Diseases

From 40 to 50 Years
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: May 2025
See protocol details

Summary

Principal SponsorMahidol University
Study ContactTippawan Pongcharoen, Ph.D.More contacts
Last updated: October 2, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 8, 2025

Actual date on which the first participant was enrolled.

1. Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women. 2. Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women. 2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women. 2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants. Screening process: 1. Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection. 2. Visit 1 (Screening): * Collect demographic and health history, measure weight, height, and body composition. * Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing. * Perform urine pregnancy test. * Administer one 400 mg albendazole tablet to prevent parasitic infection. Iron isotope administration and follow-up: 2.3.2 Eligible participants will return within 1-2 weeks for the second visit. Visit 2 (Month 0; M0): Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours. A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day). Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email. Visit 3 (Month 9; M9): Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone). Visit 4 (After 1 year; WK0): Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment. Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ. Visits 5-7 (WK8, WK16, WK24): For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ. 2.4 Research Instruments 1. General information and medical history questionnaire, 24-hour dietary recall, and FFQ. 2. Illness and menstrual record forms. 3. Anthropometry and clinical measures: * Weight: InBody digital scale * Height: Harpenden stadiometer * Body composition: Bioelectrical Impedance Analyzer (BIA; InBody) * Blood pressure: Omron digital sphygmomanometer 4. Laboratory analyses: * Hb: Complete Blood Count (CBC) using flow cytometry * SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP) * Hemoglobin typing: Capillary electrophoresis * Fasting glucose: Enzymatic method * HbA1c: Turbidimetric inhibition immunoassay * Lipids: Enzymatic colorimetric and homogeneous methods * Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software. Dietary patterns will be analyzed using Principal Component Analysis (PCA). The average iron absorption (Fe\_abs) over the study period will be calculated as: Feabs=kabs×FetotalFe\_{abs} = k\_{abs} \\times Fe\_{total}Feabs=kabs×Fetotal where Fe\_total is the total body iron at the midpoint estimated from the regression of Fe\_total over time, and k\_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time. Average iron loss (Fe\_loss) is calculated similarly: Feloss=kloss×FetotalFe\_{loss} = k\_{loss} \\times Fe\_{total}Feloss=kloss×Fetotal Iron gain (Fe\_gain) is calculated as: Fegain=Feabs-FelossFe\_{gain} = Fe\_{abs} - Fe\_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate. A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain. Statistical significance will be set at p < 0.05.

Principal SponsorMahidol University
Study ContactTippawan Pongcharoen, Ph.D.More contacts
Last updated: October 2, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

64 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 40 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightNutrition DisordersNutritional and Metabolic DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionObesityOverweight

Criteria

Inclusion Criteria: * Normal weight group 1. Aged 40-50 years 2. Normal weight (BMI 18.5-22.9 kg/m²) 3. Hb ≥12.0 g/dL and inflammation-adjusted SFa \<50.0 µg/L 4. CRP \<5.0 mg/L 5. Normal hemoglobin typing 6. Plans to reside in the study area for \>2 years * Overweight/obese group 1. Aged 40-50 years 2. Overweight or obese \[Body Mass Index (BMI) ≥25.0 kg/m²\] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA 3. Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) \<50.0 µg/L 4. C-reactive protein (CRP) between 5.0-25.0 mg/L 5. Normal hemoglobin typing 6. Plans to reside in the study area for \>2 years Exclusion Criteria: * Normal weight group 1. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure 2. Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization 3. Pregnant, breastfeeding, or planning pregnancy during the study 4. Chronic infectious disease (e.g., tuberculosis, AIDS) 5. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication) 6. Taking vitamin or mineral supplements during or within two weeks prior to the study 7. Participating in a weight-loss program 8. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling) 9. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment 10. Heavy menstrual bleeding (\>80 mL/day, calculated from menstrual record) * Overweight/obese group 1. Obesity class II (BMI ≥35.0 kg/m²) with high health risk 2. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure 3. Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization 4. Pregnant, breastfeeding, or planning pregnancy during the study 5. Chronic infectious disease (e.g., tuberculosis, AIDS) 6. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication) 7. Taking vitamin or mineral supplements during or within two weeks prior to the study 8. Participating in a weight-loss program 9. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling) 10. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment 11. Heavy menstrual bleeding (\>80 mL/day, calculated from menstrual record)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Institute of Nutrition

Nakhon Pathom, ThailandOpen Institute of Nutrition in Google Maps
Recruiting
One Study Center